179 related articles for article (PubMed ID: 18486472)
1. Structure-based prediction of Mycobacterium tuberculosis shikimate kinase inhibitors by high-throughput virtual screening.
Segura-Cabrera A; Rodríguez-Pérez MA
Bioorg Med Chem Lett; 2008 Jun; 18(11):3152-7. PubMed ID: 18486472
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, tuberculosis inhibitory activity, and SAR study of N-substituted-phenyl-1,2,3-triazole derivatives.
Costa MS; Boechat N; Rangel EA; da Silva Fde C; de Souza AM; Rodrigues CR; Castro HC; Junior IN; Lourenço MC; Wardell SM; Ferreira VF
Bioorg Med Chem; 2006 Dec; 14(24):8644-53. PubMed ID: 16949290
[TBL] [Abstract][Full Text] [Related]
3. A note on the antitubercular activities of 1-aryl-5-benzylsulfanyltetrazoles.
Adamec J; Waisser K; Kunes J; Kaustová J
Arch Pharm (Weinheim); 2005 Aug; 338(8):385-9. PubMed ID: 16041837
[TBL] [Abstract][Full Text] [Related]
4. Discovery of bicyclic thymidine analogues as selective and high-affinity inhibitors of Mycobacterium tuberculosis thymidine monophosphate kinase.
Vanheusden V; Munier-Lehmann H; Froeyen M; Busson R; Rozenski J; Herdewijn P; Van Calenbergh S
J Med Chem; 2004 Dec; 47(25):6187-94. PubMed ID: 15566289
[TBL] [Abstract][Full Text] [Related]
5. 3D-QSAR studies on antitubercular thymidine monophosphate kinase inhibitors based on different alignment methods.
Aparna V; Jeevan J; Ravi M; Desiraju GR; Gopalakrishnan B
Bioorg Med Chem Lett; 2006 Feb; 16(4):1014-20. PubMed ID: 16290929
[TBL] [Abstract][Full Text] [Related]
6. Structure of shikimate kinase from Mycobacterium tuberculosis reveals the binding of shikimic acid.
Pereira JH; de Oliveira JS; Canduri F; Dias MV; Palma MS; Basso LA; Santos DS; de Azevedo WF
Acta Crystallogr D Biol Crystallogr; 2004 Dec; 60(Pt 12 Pt 2):2310-9. PubMed ID: 15583379
[TBL] [Abstract][Full Text] [Related]
7. Interaction of shikimic acid with shikimate kinase.
Pereira JH; de Oliveira JS; Canduri F; Dias MV; Palma MS; Basso LA; de Azevedo WF; Santos DS
Biochem Biophys Res Commun; 2004 Dec; 325(1):10-7. PubMed ID: 15522194
[TBL] [Abstract][Full Text] [Related]
8. Ligand-based virtual screening, parallel solution-phase and microwave-assisted synthesis as tools to identify and synthesize new inhibitors of mycobacterium tuberculosis.
Manetti F; Magnani M; Castagnolo D; Passalacqua L; Botta M; Corelli F; Saddi M; Deidda D; De Logu A
ChemMedChem; 2006 Sep; 1(9):973-89. PubMed ID: 16892466
[TBL] [Abstract][Full Text] [Related]
9. Antifungal and antimycobacterial activity of new imidazole and triazole derivatives. A combined experimental and computational approach.
Banfi E; Scialino G; Zampieri D; Mamolo MG; Vio L; Ferrone M; Fermeglia M; Paneni MS; Pricl S
J Antimicrob Chemother; 2006 Jul; 58(1):76-84. PubMed ID: 16709593
[TBL] [Abstract][Full Text] [Related]
10. Molecular model of shikimate kinase from Mycobacterium tuberculosis.
Filgueira de Azevedo W; Canduri F; Simões de Oliveira J; Basso LA; Palma MS; Pereira JH; Santos DS
Biochem Biophys Res Commun; 2002 Jul; 295(1):142-8. PubMed ID: 12083781
[TBL] [Abstract][Full Text] [Related]
11. Comparative protein modeling of methionine S-adenosyltransferase (MAT) enzyme from Mycobacterium tuberculosis: a potential target for antituberculosis drug discovery.
Khedkar SA; Malde AK; Coutinho EC
J Mol Graph Model; 2005 Jan; 23(4):355-66. PubMed ID: 15670956
[TBL] [Abstract][Full Text] [Related]
12. A virtual screening approach for thymidine monophosphate kinase inhibitors as antitubercular agents based on docking and pharmacophore models.
Gopalakrishnan B; Aparna V; Jeevan J; Ravi M; Desiraju GR
J Chem Inf Model; 2005; 45(4):1101-8. PubMed ID: 16045305
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of phosphoryl transfer catalyzed by shikimate kinase from Mycobacterium tuberculosis.
Hartmann MD; Bourenkov GP; Oberschall A; Strizhov N; Bartunik HD
J Mol Biol; 2006 Dec; 364(3):411-23. PubMed ID: 17020768
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of novel 5-aryl-2-thio-1,3,4-oxadiazoles and the study of their structure-anti-mycobacterial activities.
Macaev F; Rusu G; Pogrebnoi S; Gudima A; Stingaci E; Vlad L; Shvets N; Kandemirli F; Dimoglo A; Reynolds R
Bioorg Med Chem; 2005 Aug; 13(16):4842-50. PubMed ID: 15993090
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and characterization of novel hydrazide-hydrazones and the study of their structure-antituberculosis activity.
Bedia KK; Elçin O; Seda U; Fatma K; Nathaly S; Sevim R; Dimoglo A
Eur J Med Chem; 2006 Nov; 41(11):1253-61. PubMed ID: 16919372
[TBL] [Abstract][Full Text] [Related]
16. Crystallographic studies of shikimate binding and induced conformational changes in Mycobacterium tuberculosis shikimate kinase.
Dhaliwal B; Nichols CE; Ren J; Lockyer M; Charles I; Hawkins AR; Stammers DK
FEBS Lett; 2004 Sep; 574(1-3):49-54. PubMed ID: 15358538
[TBL] [Abstract][Full Text] [Related]
17. Improved lead-finding for kinase targets using high-throughput docking.
McInnes C
Curr Opin Drug Discov Devel; 2006 May; 9(3):339-47. PubMed ID: 16729730
[TBL] [Abstract][Full Text] [Related]
18. Discovery of Helicobacter pylori shikimate kinase inhibitors: bioassay and molecular modeling.
Han C; Zhang J; Chen L; Chen K; Shen X; Jiang H
Bioorg Med Chem; 2007 Jan; 15(2):656-62. PubMed ID: 17098431
[TBL] [Abstract][Full Text] [Related]
19. Novel 1,4-substituted-1,2,3-triazoles as antitubercular agents.
Altimari JM; Hockey SC; Boshoff HI; Sajid A; Henderson LC
ChemMedChem; 2015 May; 10(5):787-91. PubMed ID: 25788466
[TBL] [Abstract][Full Text] [Related]
20. Identification of heteroarylenamines as a new class of antituberculosis lead molecules.
Copp BR; Christiansen HC; Lindsay BS; G Franzblau S
Bioorg Med Chem Lett; 2005 Sep; 15(18):4097-9. PubMed ID: 16005211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
